<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157312</url>
  </required_header>
  <id_info>
    <org_study_id>MU-290s</org_study_id>
    <secondary_id>FMH-212-G</secondary_id>
    <nct_id>NCT01157312</nct_id>
  </id_info>
  <brief_title>Minimal Stimulation or Clomiphene Citrate in Treatment of Polycystic Ovary Syndrome</brief_title>
  <official_title>Minimal Stimulation or Clomiphene Citrate as First Line Therapy in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and determine the the efficacy of minimal stimulation
      and clomiphene citrate(CC) as the first-line treatment in infertile women with Polycystic
      Ovary Syndrome(PCOS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients received 100 mg CC (ClomidÂ®; Global Napi Pharmaceuticals, Cairo, Egypt) for 5
      days starting from day 3 of spontaneous or induced menstruation. In group A (minimal
      stimulation), 2 vials of highly purified uFSH , 150 IU (Fostimon; IBSA, Lugano, Switzerland,
      75 IU/vial) were given IM on cycle day 9. A total of 3 cycles was offered to each group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate per cycle</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness at the time of hCG administration</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>minimal stimulation protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 days of CC (100mg/day) from day 3 followed by 150 IU of highly purified uFSH on cycle day 9 for three treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clomiphene citrate(CC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 days of CC (100mg/day) from cycle day 3 for three treatment cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomiphene citrate +highly purified uFSH</intervention_name>
    <arm_group_label>minimal stimulation protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomiphene citrate</intervention_name>
    <arm_group_label>clomiphene citrate(CC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS

          -  No other infertility factors

          -  No previous use of ovarian stimulation drugs

        Exclusion Criteria:

          -  Congenital adrenal hyperplasia

          -  Cushing syndrome

          -  Androgen secreting tumors
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hatem Abu Hashim, MD MRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed F Bazeed, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim Abd Elaal, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University Hospitals,OB/GYN department</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia Governorate</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Lu PY, Chen AL, Atkinson EJ, Lee SH, Erickson LD, Ory SJ. Minimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility. Fertil Steril. 1996 Mar;65(3):583-7.</citation>
    <PMID>8774291</PMID>
  </reference>
  <reference>
    <citation>Houmard BS, Juang MP, Soules MR, Fujimoto VY. Factors influencing pregnancy rates with a combined clomiphene citrate/gonadotropin protocol for non-assisted reproductive technology fertility treatment. Fertil Steril. 2002 Feb;77(2):384-6.</citation>
    <PMID>11821101</PMID>
  </reference>
  <reference>
    <citation>Dhaliwal LK, Sialy RK, Gopalan S, Majumdar S. Minimal stimulation protocol for use with intrauterine insemination in the treatment of infertility. J Obstet Gynaecol Res. 2002 Dec;28(6):295-9.</citation>
    <PMID>12512925</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2010</study_first_posted>
  <last_update_submitted>July 16, 2010</last_update_submitted>
  <last_update_submitted_qc>July 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hatem Abu Hashim, Associate Prof. of OB/GYN</name_title>
    <organization>Mansoura Faculty of Medicine, Mansoura University.</organization>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>clomiphene citrate</keyword>
  <keyword>minimal stimulation</keyword>
  <keyword>infertility treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

